Indeed, KIF14-silencing markedly enhanced the sorafenib-sensitivity of tumor cells, which could be further bolstered through the combination of KIF14-intervention and sorafenib treatment, implying that this protein may underlie sorafenib resistance in HCC. The gene discussed is KIF14; the disease is neoplasm.